skip to main content
Idioma:

Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review

Sodré-Alves, Bárbara Manuella Cardoso ; Toledo, Melina Mafra ; Zimmermann, Ivan Ricardo ; Araújo, Wildo Navegantes de ; Tavares, Noemia Urruth Leão

Revista da Sociedade Brasileira de Medicina Tropical, 2024-01, Vol.57, p.e004022024-e004022024 [Periódico revisado por pares]

Brazil: Sociedade Brasileira de Medicina Tropical - SBMT

Texto completo disponível

Citações Citado por
  • Título:
    Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review
  • Autor: Sodré-Alves, Bárbara Manuella Cardoso ; Toledo, Melina Mafra ; Zimmermann, Ivan Ricardo ; Araújo, Wildo Navegantes de ; Tavares, Noemia Urruth Leão
  • Assuntos: Antitubercular Agents - adverse effects ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Isoniazid ; Isoniazid - adverse effects ; Latent Tuberculosis - drug therapy ; Latent tuberculosis infection ; Major ; Medication safety ; Rifampin ; Treatment adherence ; Treatment effectiveness ; TROPICAL MEDICINE ; Tuberculosis - drug therapy
  • É parte de: Revista da Sociedade Brasileira de Medicina Tropical, 2024-01, Vol.57, p.e004022024-e004022024
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    ObjectType-Undefined-3
    Conflict of Interest: The authors declare that they have no conflicts of interest.
  • Descrição: The treatment strategy for latent tuberculosis infection is to reduce the number of tuberculosis cases and consequently reduce the transmission of pathogenic bacteria. This study aimed to determine the safety, effectiveness, and adherence of isoniazid use for latent tuberculosis infection treatment. To identify studies on isoniazid use for latent tuberculosis infection, five electronic databases were searched. The methods and results are presented in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Most studies (53) used isoniazid for 9 months. The prevalence of use and adherence to treatment varied considerably (18% to 100%), and were evaluated by participant completion of isoniazid treatment for latent tuberculosis infection. The adverse events most frequently reported were hepatotoxicity, gastric intolerance, and neuropathy; the rates of occurrence ranged from < 1% to 48%. In the studies that evaluated the effectiveness of isoniazid for latent tuberculosis infection, the rate varied from 0 to 19.7% for patients who did not have active tuberculosis after the follow-up period. The importance of maintaining follow up for patients using isoniazid should be emphasized due to the risk of developing adverse events. Despite the treatment challenges, the rates of patients who used isoniazid and developed active tuberculosis during the follow-up period were low. We believe that isoniazid continues to contribute to tuberculosis control worldwide, and better care strategies are required.
  • Editor: Brazil: Sociedade Brasileira de Medicina Tropical - SBMT
  • Idioma: Inglês;Português
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.